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ity that underlies tumorigenesis and the 
development of metastasis. Recently, our 
group developed a bioinformatics strate-
gy termed Cancer Outlier Profile Analysis 
(COPA) in an effort to identify “oncogene 
outliers,” or genes with marked overex-
pression in a fraction of cases, which 
characterize genes involved in high-level 
copy number changes or translocations, 
such as those described above. COPA 
identified the Ets transcription factors 
ERG and ETV1 as outliers across mul-
tiple prostate cancer profiling studies. 
Characterizing cases with overexpres-
sion of ERG or ETV1, we demonstrated 
that these samples harbored recurrent 
gene fusions with the androgen-regulat-
ed gene TMPRSS2, and these fusions 
occur in the majority of prostate cancers 
(Tomlins et al., 2005). This approach was 
useful in the analysis of tumors without 
biologically relevant mouse models and 
may prove useful in mining mouse mod-
els of cancer as well.
In addition to using mouse models 
or bioinformatic strategies, other groups 
have used alternative integrative analy-
ses to identify driving genetic events in 
tumorigenesis. For example, Garraway et 
al. performed an integrative analysis com-
bining gene expression and copy number 
profiles of the NCI60 panel of cancer cell 
lines to identify and validate MITF as a 
lineage-specific oncogene amplified in a 
subset of melanomas (Garraway et al., 
2005). Adler et al. also integrated expres-
sion and copy number profiles from breast 
cancers to identify coordinated amplifica-
tion of Myc and CSN5 as a regulator of the 
wound response profile that is predictive 
of poor outcome (Adler et al., 2006).
Amassing genomic scale data for 
human tumors is becoming relatively 
routine. The rapid advancement of 
high-throughput techniques suggests 
that complete genomic profiles of 
tumor samples may soon be realized. 
Integrative approaches will be needed to 
sift through this mass of data to identify 
the driving genetic lesions underlying 
cancer development and progression. 
The results of Zender et al. and Kim et al. 
demonstrate that integrative approaches 
based on defined mouse models can 
be used as one such method to identify 
driving oncogenic or metastatic events 
in human tumors.
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A fundamental property of cancer cells is the preferential utilization of glycolysis over aerobic respiration to produce ATP. 
Renewed interest in understanding the mechanism underlying this metabolic shift in energy production is broadening our 
understanding of the relationship between cancer and cellular metabolism. In a recent article, Matoba et al. report that the p53 
tumor suppressor regulates the expression of SCO2, a protein that is required for the assembly of cytochrome c oxidase (COX), 
a multimeric protein complex required for oxidative phosphorylation. The implication of these findings is that aerobic respira-
tion is compromised in cells that lack functional p53.In contrast to normal cells, cancer cells 
have a high glycolytic rate and produce 
high levels of lactate even in the pres-
ence of oxygen (Figure 1). This metabolic 
shift to a higher rate of aerobic glycolysis 
is commonly referred to as the Warburg 
effect. Because glycolysis produces ener-
gy (ATP) far less efficiently than aerobic 
	respiration, tumor cells have a much high-
er rate of glucose uptake than normal cells 
(Figure 1). The physiological significance 
of the Warburg effect has been controver-
sial since its discovery over 80 years ago, 
and now there is renewed and vigorous 
interest in understanding the relation-
ship between cancer and altered energy metabolism. A commonly held view is that 
constitutive upregulation of glycolysis is 
likely to be an adaptation to hypoxia that 
develops as tumor cells grow progres-
sively further away from their blood supply 
(Gatenby and Gillies, 2004). Interestingly, 
cells derived from tumors continue to uti-
lize glycolysis in culture under normoxic cancer cell July	2006
	 p r e v i e w sconditions, suggesting that stable genetic 
or epigenetic changes may account for 
this metabolic shift toward glycolysis.
The molecular mechanisms underly-
ing the Warburg effect are uncertain and 
remain controversial. It is unclear if the 
defect lies within glycolysis, in oxidative 
phosphorylation, or in the pathways that 
modulate cellular metabolism. The shift 
from aerobic mitochondrial respiration 
to glycolysis in tumor cells could be the 
result of increased activity of glycolytic 
enzymes, decreased utilization of pyru-
vate by mitochondria, reduced capacity to 
transport cytosolic NADH into mitochon-
dria through mitochondrial NADH/NAD+ 
shuttle pathways, impaired tricarboxylic 
cycle, or defects in respiration at various 
points in the electron transport chain.
HIF-1α, a protein that is stabilized 
under hypoxic conditions and associates 
with HIF-1β to form a heterodimeric tran-
scription factor, has been implicated as an 
important regulator of glycolysis through 
its ability to increase the expression of 
genes encoding glucose transporters and 
glycolytic enzymes (Semenza, 2003). In 
addition to promoting glycolysis, HIF-1 
has been shown to suppress both the TCA 
cycle and aerobic respiration by inducing 
pyruvate dehydrogenase kinase 1 (PDK1) 
(Kim et al., 2006; Papandreou et al., 2006). 
PDK1 phosphorylates and inactivates the 
TCA cycle enzyme, pyruvate dehydroge-
nase (PDH), which converts pyruvate to 
acetyl-CoA. Deregulated c-MYC expres-
sion also enhances aerobic glycolysis by 
directly upregulating the expression of gly-
colytic genes independent of hypoxia (Kim 
et al., 2004). AKT activation increases 
glucose transport and glycolysis and ren-
ders cancer cells dependent on glucose 
availability for their survival (Elstrom et al., 
2004). HIF-1 expression, PI3K/AKT acti-
vation, and c-MYC expression are com-
mon in many cancers.
Recent findings aimed at understand-
ing the basis for constitutive aerobic gly-
colysis in cancer cells are provocative and 
insightful. A report by Matoba et al. (2006) 
invokes p53 as a determinant of ATP pro-
duction through regulation of mitochondrial 
oxidative phosphorylation. They report that 
p53 regulates the expression of SCO2 (for 
synthesis of cytochrome c oxidase), a 
nuclear gene that encodes a copper bind-
ing protein that is required for the assem-
bly of cytochrome c oxidase (COX). COX 
is a multimeric protein complex (complex 
IV of the respiratory chain) that is embed-
ded in the inner mitochondrial membrane. cancer cell July	2006	It catalyzes the transfer of electrons from 
reduced cytochrome c to molecular oxygen 
in the terminal step of the respiratory chain 
and pumps protons from the mitochondrial 
matrix to the intermembrane space. COX 
is composed of 13 structural subunits; sub-
units I–III are encoded by the mitochondrial 
genome and constitute the catalytic core 
of the enzyme, and the remaining ten sub-
units are encoded by the nuclear genome. 
In humans, mutations in SCO2 cause fatal 
infantile COX deficiency with the predomi-
nant symptoms being early onset hypertro-
phic cardiomyopathy and encephalopathy 
due to failure in holoenzyme assembly 
(Esteitie and Larsson, 2004).
Matoba et al. (2006) show that oxygen 
consumption (a measure of aerobic res-
piration) is lower in a preparation of liver 
mitochondria from p53-deficient mice 
compared with wild-type mice. A reduc-
tion in oxygen consumption is also seen 
in human HCT116 p53−/− cells compared 
with HCT116 p53+/+ cells. ATP production 
is similar in p53+/+ and p53−/− HCT116 cells, Figure 1.	ATP	production	by	glycolysis	and	aerobic	respiration
The	first	stage	of	glycolysis	(the	breakdown	of	glucose	and	its	conversion	to	pyruvate)	occurs	in	the	
cytoplasm	and	serves	as	an	obligatory	preparatory	step	for	aerobic	respiration,	which	occurs	in	mito-
chondria.	under	aerobic	conditions,	pyruvate	is	not	normally	reduced	to	lactate	but	is	oxidized	directly	
to	acetyl-CoA	for	entry	into	the	tricarboxylic	cycle	(TCA	or	Krebs	cycle).	In	addition,	the	cytoplasmic	
NADH	produced	during	glycolysis	is	not	oxidized	by	pyruvate	but	rather	by	the	electron	transport	chain	
after	shuttle-mediated	entry	of	NADH	into	mitochondria.	In	the	absence	of	oxygen,	the	conversion	of	
pyruvate	to	lactate	by	lactate	dehydrogenase	regenerates	NAD+,	which	is	essential	for	glycolysis.but lactate production (a measure of gly-
colysis) is higher in the p53−/− cells. These 
data indicate that loss of p53 results in a 
metabolic shift away from aerobic respi-
ration toward the production of glycolytic 
ATP. The missing link that connects p53 
with aerobic respiration turns out to be 
SCO2, identified initially by SAGE analysis 
as a p53-regulated gene and subsequent-
ly by protein analysis. The protein data are 
striking and show that the basal level of 
SCO2 protein in unstressed HCT116 cells 
as well as in mouse liver mitochondria is 
dependent on p53 gene dosage. This is 
confirmed by siRNA-mediated knock-
down of p53 expression in HCT116 cells, 
which results in a decrease in the level of SCO2 protein and a decrease in oxygen 
consumption. A clear and unambiguous 
conclusion from these experiments is 
that endogenous p53 in unstressed cells 
regulates the steady-state level of SCO2 
protein to facilitate aerobic respiration. 
Whether this occurs through direct tran-
scriptional activation of SCO2 is arguable. 
The presumed p53 response element in 
intron 1 of human SCO2 does not resem-
ble a typical p53 consensus motif (only 
14 of 20 residues are conserved), and it 
contains nucleotides at certain positions 
of the consensus that are rarely seen in 
well-characterized target genes (Miled et 
al., 2005). Since significant degeneracy 
can occur in the p53 consensus sequence 
of p53-responsive genes, a ChIP experi-
ment would demonstrate whether p53 
binds directly to this site in vivo. Matoba 
et al. (2006) also report that p53 null mice 
tire more easily than normal mice when 
subjected to a swim endurance test using 
an adjustable current swimming pool pro-
tocol. The interpretation provided is that p53 null mice exhibit a decrease in func-
tional aerobic capacity. At the time of the 
endurance test, these mice were between 
9 and 20 weeks of age. Most of these mice 
will die of lymphoma within 6 months of 
age and hence may have been very sick 
at the time of testing. So the results of this 
test need to be interpreted cautiously. This 
is a fascinating observation that reveals 
a novel and important phenotype of p53-
deficient mice. Confirmation, possibly with 
neonatal mice, is needed.
Two previous studies had established 
a relationship between glucose metabo-
lism and p53. Inhibition of glycolysis by 
glucose withdrawal was shown to serve as 
a signal for the phosphorylation and acti-
	 p r e v i e w svation of p53 (Jones et al., 2005; Feng et 
al., 2005). It will be of interest to determine 
if SCO2 expression is further enhanced 
by p53 under stress conditions such as 
glucose deprivation.
Fantin et al. (2006) reported that sup-
pression of aerobic lactate production 
upon shRNA-mediated knockdown of 
lactate dehydrogenase A (LDH-A) in neu-
initiated mammary tumor cells resulted 
in increased oxygen consumption and 
increased mitochondrial oxidative phos-
phorylation. Hence, tumor cells retain the 
ability to generate ATP through aerobic 
respiration when aerobic glycolysis is 
blocked. Fantin et al. (2006) suggest that 
preferential utilization of NADH by LDH-
A in the cytosol impedes mitochondrial 
respiration. Intriguingly, LDH-A-deficient 
tumor cells exhibited decreased prolifera-
tive and tumorigenic potential, supporting 
the long-held view that glycolysis provides 
tumor cells with a selective growth advan-
tage. Fantin et al. (2006) note that some 
tumors had a strict LDH-A requirement 
and underwent apoptosis upon transient 
expression of LDH-A shRNA-expressing 
vectors. This indicates that reversion from 
aerobic glycolysis to mitochondrial respira-
tion is not possible in all tumors and sug-
gests that irreversible genetic or epigenetic 6	changes may have occurred to prevent the 
metabolic switch. In light of the results by 
Matoba et al. (2006), it would be of consid-
erable interest to determine if tumors with 
a strict LDH-A requirement have sustained 
mutations in p53 or in components of the 
p53 pathway.
In summary, after 80 years, the 
Warburg effect remains enigmatic. The 
paper by Matoba et al. (2006) resurrects 
the idea that enhanced aerobic glycoly-
sis results from tumor-specific mutations 
that modulate oxidative phosphorylation. 
Importantly, this study introduces a new 
player—p53—into the field of cellular 
metabolism.
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